Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

 Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shots:

  • The P-II CheckMate -650 trial involves assessing of Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab, 3mg/kg) in patients with mCRPC
  • P-II study result in asymptomatic or minimally symptomatic patients & patients who progressed after taxane-based CT ORR @ 11.9/13.5 mos. (25%, 10%); GRADE 3AEs or 5AEs (42%, 53%), Presented at ASCO 2019
  • Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor targeted for cancer cells and is approved in 65 countries including the US, EU, Japan & China

Click here to read full press release/ article | Ref: BMS | Image: Axios

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post